Organovo首席执行官基思·墨菲（Keith Murphy）参加了第二季度（2017财年）分析师和投资者的电话，知道他将处于一些潜在的敌对问题的接收端。在该公司启动新的股权融资后，在10月份的3D生物印刷公司股票中，几乎损失了其价值的三分之一。
As reported by 3DPI,计划在10月筹集2500万美元via a new offering of shares saw the company’s share price take a 15% hit as investors saw existing holdings diluted with the offer pricing the company at $2.75 per share. Furthermore, SEC filings show Organovo Chief Strategy Officer David Eric had earlier sold shares at $4.55 during August. Shares in the company were last traded at $2.54.
如此短期的价格波动似乎并没有阻止投资者，而这场2500万美元的筹款回合在3天内完成。此外，在投资者中，分析师似乎对筹集资金的基本原理感到满意，并且至少在公共场合没有进一步向首席执行官基思·墨菲（Keith Murphy）提出。
收入增加了两倍
这些最新结果的看法，有机诺的收入超过了三倍，总计140万美元，而2015年同期的3.01亿美元。昨天的电话首席执行官墨菲说：“these gains represent a significant inflection point。”
Organovohave already commercialized several medical products but Murphy is adamant that this is just a first step, “尽管我们可以停止扩展临床前组织测试业务并专注于盈利能力，但这种方法不允许我们充分利用平台技术。”
Our investments don’t end with our ExVive Human Liver and Kidney Tissue Services, although we’ll certainly focus on accelerating adoption of our existing commercial products.
30亿美元的可寻址市场
首席执行官认为，通过引入肝脏和肾脏的代谢产品，他们可以进入肝脏和组织服务的双重市场。将这项服务带入市场需要对设备的投资，包括质谱仪，还增加了当前115名员工的员工。
Organovo的运营费用和成本清楚地说明了生物技术的资本密集型性质。17年代第二季度的总费用和费用为1,080万美元（17 Q2’17美元1760万美元）。在此期间，由于停止使用外包资源，对研发的支出降低了4％。此外，由于2名前高管的非重新分离费用降低，销售，一般和行政（SGA）费用减少了14％。
Despite marginally reductions costs still remain high, and in excess of revenue. Murphy explained that such expenses are necessary in order for the company to access the “30亿美元是总可寻址市场”用于Organovo产品。首席执行官还提供了一些信息，这些信息可以看着前25家大型制药公司，Organovo现在将10视为客户，在此期间增加了3个。但是，墨菲不会在其中有多少个是回头客的主题以及个人合同的具体价值。
However, the pace of sales is set to pick up according to Murphy. This is due to the favorably reception of several research studies by the company, and also the relationships they have built with customers. “我们最近在两种受人尊敬的期刊《 PLOS One》和毒理学的出版物无疑是客户采用的主要驱动力，”墨菲说。
推出了新产品
Organovonow have $75 million of cash on hand to invest in their business plan and will deploy capital to scale the toxicology business and expand range of products, they will also invest to expand into new markets. Cash requirements are forecast at $30 million going forward, a number that the company believe will come down. One such new product, launched in September, is their Kidney Tissue service.
The kidney proximal tubule model is a natural expansion of our preclinical product and service portfolio, allowing customers to study the effects of drug exposure on a key portion of the human kidney relevant to drug discovery and development. With just several weeks under our belt since launch, we’ve already signed multiple commercial orders with several companies. Early adopters, such as Ardea Biosciences, a subsidiary of AstraZeneca and the La Jolla Pharmaceutical, have provided strong feedback on the product and how they’re integrating it into their drug programs.
在他们的治疗组织业务中，早期的临床前结果是有希望的。根据墨菲的说法，动物研究表明了包括“在血清中可检测到的功能。”与生物技术行业几乎所有的东西一样，这不是一个短期项目，”我们在优化和选择最终的组织设计以及通过前GLP和GLP疗效和安全研究中仍有很多工作要做，然后才能在接下来的三到五年内提交IND。”
但是，该公司对其产品有一个渴望的市场，首席执行官解释说，这是因为缺乏替代方案。使用Organovo产品，几家大型制药公司已经开始重新调查进度停滞的药品。
Organovoalso gave an update on三星Sciences Inc.，他们于2016年1月成立的子公司。三星供应有机诺（Samsara Supply Organovo），包括肝细胞在内，用于3D打印。墨菲解释说，他们不会提供有关财务信息的详细数字，但是子公司“yields a lot more value than just revenue” as it delivers cells to other areas of business. Liver cells are both costly and can be difficult to source.
投资者的疯狂旅程
Organovoare one of the most recognizable faces of 3D bio-printing, and as a publicly traded company are subject to a higher degree of scrutiny than others operating in this sector. These most recent results demonstrate a promising trend in revenue, but profitability is still someway off. Biotech investments are viewed by investors as highly speculative, and investors stung by October’s dilution may be less willing to give the company a second chance. However, for the brave the company may offer a wild ride.
完整的财务业绩可用这里.
特色图显示了Organovo的Novogen BioProinter™将组织制造成24孔板。照片通过Organovo.
